Provectus Biopharmaceuticals (PVCT)

Provectus Biopharmaceuticals, Inc. is a development stage biopharmaceutical company. It engages in the development of ethical pharmaceuticals for oncology and dermatology indications. Its prescription drugs treats several life threatening cancers including metastatic melanoma, liver cancer, and breast cancer. The company was founded by Eric A. Wachter in 2002 and is headquartered in Knoxville, TN.

Company profile

Ticker

PVCT

Exchange

NASDAQ

Website

www.provectusbio.com/

CEO

Bruce Horowitz

Incorporated

Delaware

Location

Tennessee

Fiscal year end

Dec 31

Sector

Manufacturing > Pharmaceutical Preparation Manufacturing

Industry (SIC)

Pharmaceutical Preparations

Pfizer • Johnson & Johnson • Merck & Co • Allergan • Abbott Laboratories • Teva- Pharmaceutical Industries • Lilly(Eli) & Co • Bristol-Myers Squibb • Viatris • Abbvie ...

Former names

PROVECTUS PHARMACEUTICAL INC, PROVECTUS PHARMACEUTICALS INC, SPM GROUP INC, ZAMAGE DIGITAL IMAGING INC

SEC CIK

0000315545

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Indentures

Material Contracts & Credit Agreements

Subsidiaries Lists

IRS number

900031917

PVCT stock data

1M 1Y 5Y

Press releases

From Benzinga Pro

Provectus Biopharmaceuticals Expands Sponsored Research Collaboration with University of Calgary (Canada) to Investigate Systemic Administration of Pharmaceutical-Grade Rose Bengal for Treatment of Pediatric Leukemia

17 Aug 22

KNOXVILLE, TN, Aug. 17, 2022 (GLOBE NEWSWIRE) -- Provectus (OTCQB:PVCT) today announced that the Company has expanded its sponsored research program with Aru Narendran, MD, PhD, Professor, Departments of Pediatrics,

Provectus Biopharmaceuticals Presents Data from PV-10® Treatment of Metastatic Uveal Melanoma Patients in Two Oral Presentations at 2022 International Society of Ocular Oncology (ISOO) Congress

30 Jun 22

KNOXVILLE, TN, June 30, 2022 (GLOBE NEWSWIRE) -- Provectus (OTCQB:PVCT) today announced that updated data from the Company's initial expansion cohort of patients with uveal melanoma metastatic to the liver (mUM) in its

Provectus Biopharmaceuticals Announces Stockholder Approval to Undertake Reverse Split of Outstanding Equities and Reduce Number of Authorized Equities by Same Ratio

23 Jun 22

KNOXVILLE, TN, June 23, 2022 (GLOBE NEWSWIRE) -- Provectus (OTCQB:PVCT) today announced that the Company's shareholders have approved the proposals of Provectus' Board of Directors (Board) to seek the authority to

Investment data

Data from SEC filings

Securities sold

Number of investors

Calendar

11 Aug 22

19 Aug 22

31 Dec 22

Financial summary

Financial statements Chart PVCT financial data

Quarter (USD)	Jun 22	Mar 22	Dec 21	Sep 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 21	Sep 21	Dec 20	Dec 19
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	2.03M	2.03M	2.03M	2.03M	2.03M	2.03M
Cash burn (monthly)	149.47K	(no burn)	359.33K	362.3K	292.63K	55.32K
Cash used (since last report)	251.43K	n/a	604.45K	609.45K	492.25K	93.05K
Cash remaining	1.78M	n/a	1.43M	1.42M	1.54M	1.94M
Runway (months of cash)	11.9	n/a	4.0	3.9	5.3	35.1

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Recent insider trades

PVCT insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	#Shares	#Remaining
20 Jun 21	Eric PHD Wachter	Series D-1 Convertible Preferred Stock Common Stock	Option exercise	Acquire M	No	No	1,393,276	1,393,276
20 Jun 21	Bruce Horowitz	Series D-1 Convertible Preferred Stock Common Stock	Option exercise	Acquire M	No	No	38,473	38,473
20 Jun 21	Pershing Edward	Series D-1 Convertible Preferred Stock Common Stock	Option exercise	Acquire M	No	No	478,926	478,926

Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

Institutional ownership, Q2 2022

PVCT institutional ownership history Ownership history

0.0% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	5	3	+66.7%
Opened positions	2	0	NEW
Closed positions	0	1	EXIT
Increased positions	0	0
Reduced positions	0	0

13F shares	Current	Prev Q	Change
Total value	11K	8K	+37.5%
Total shares	190.4K	120K	+58.7%
Total puts	0	0
Total calls	0	0
Total put/call ratio	–	–	–

Largest owners	Shares	Value	Change
Home Federal Bank Of Tennessee	100K	$6K	0.0%
Diversified Trust	50K	$3K	NEW
Captrust Financial Advisors	20.4K	$1K	NEW
Academy Capital Management	20K	$1K	0.0%
Huntington National Bank	1	$0	0.0%

Largest transactions	Shares	Bought/sold	Change
Diversified Trust	50K	+50K	NEW
Captrust Financial Advisors	20.4K	+20.4K	NEW
Huntington National Bank	1	0	0.0%
Academy Capital Management	20K	0	0.0%
Home Federal Bank Of Tennessee	100K	0	0.0%

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Financial report summary

Competition

Crinetics Pharmaceuticals

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. freshman Avg

New words: approach, Chief, Council, discretion, good, Harmonization, moved, practice, proportional, proposal, recommendation, renewed, reverse, split, stockholder, Technical

Removed: activity, advisory, atopic, breast, carcinoma, cell, colorectal, entered, equivalent, Ewing, FDA, Food, gastrointestinal, GI, granted, HCC, head, hepatocellular, led, leukemia, liver, lung, mCRC, melanoma, metastatic, mNET, mUM, murine, neck, neuroblastoma, neuroendocrine, ocular, ODD, Orphan, osteosarcoma, reportedly, rhabdomyosarcoma, sarcoma, testicular, transformation, uveal

From filing 10-Q 2022 Q2

Financial reports

View all